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Abstract
Background. A growing body of evidence suggests that effective blood pressure reduction may inhibit the progression of
microvascular damage in patients with essential arterial hypertension. However, the potential inﬂuence of anti-hypertensive
drugs on ocular circulation has not been studied sufﬁciently.
Purpose. The aim of our study was to evaluate the effects of anti-hypertensive therapy on blood ﬂow in the central retinal artery
in patients with systemic arterial hypertension.
Material and methods. Twenty patients with essential arterial hypertension, aged 32–46 years, were examined with Doppler
ultrasonography (10 MHz ultrasound probe). Blood ﬂow velocities, pulsatility, and vascular resistance were determined before
and 3 hours after systemic application of either bisoprolol 5 mg or cilazapril 2.5 mg.
Results. Administered bisoprolol signiﬁcantly decreased maximum (9.8 ± 0.5 cm/s versus 8.5 ± 0.6 cm/s; P < 0.05) and
minimum (2.75 ± 0.19 cm/s versus 1.75 ± 0.27 cm/s; P < 0.02) velocity, increased the Pourcellot’s index (0.71 to 0.79;
P < 0.05) in central retinal artery. There were no statistically signiﬁcant changes in central retinal artery blood ﬂow after
administration of cilazapril.
Conclusion. Systemic application of beta-blockers may unfavourably disturb the ocular blood ﬂow.
Key words: Bisoprolol, central retinal artery, cilazapril, Doppler ultrasonography
Introduction
Systemic arterial hypertension gradually contributes
to progressive damage of arterial vessels. Chronic
increases in blood pressure cause several responses
within the microvasculature, including endothelial
dysfunction, impaired vessel relaxation, enhanced
contractile response, and complex intima-media
thickening. Finally, hypertrophy and proliferation of
vascular smooth muscle cells decrease lumen diam-
eter, which is accompanied by an increase in vessel
resistance (1). It is well known that effective reduction
of blood pressure may slow down progression of
small arteries’ damage. Recent guidelines for the
management of arterial hypertension focus on the
necessity of intensive blood pressure lowering.
Clinical trials have clearly shown that several
classes of drugs, including beta-blockers (BB) and
angiotensin-converting enzyme inhibitors (ACEI),
reduce the complications of systemic hypertension
(2). Whereas beta-adrenergic receptors and compo-
nents of tissue renin-angiotensin system (RAS) recep-
tors have been localized within the ophthalmic
circulation (3–6), potential unfavourable anti-
hypertensive drug effects on ocular blood ﬂow must
be considered before pharmacotherapy selection.
Among glaucoma vascular risk factors, special atten-
tion is paid to systemic arterial hypertension,
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dippers’). Moreover, patients with hypertension
reveal impaired physiological ocular blood ﬂow
auto-regulation with range shifted toward higher
intra-ocular pressure (IOP) values, which sensitizes
them to lower systemic blood pressure (7).
According to our knowledge, data concerning
inﬂuence of different anti-hypertensive drugs applied
systemically on ocular blood ﬂow in humans are very
scarce. Therefore the aim of our study was to evaluate
the inﬂuence of BB (bisoprolol) and ACEI (cilazapril)
on central retinal artery (CRA) ﬂow assessed with
Doppler ultrasonography in patients with systemic
arterial hypertension.
Patients and methods
We enrolled 20 patients (aged 32–46 years) with a
newly diagnosed essential arterial hypertension
requiring monotherapy with one of the anti-
hypertensive drugs. Patients were divided into two
study groups consisting of 10 patients each and were
given orally once (one single dose) either cilazapril
2.5mg(Inhibace;Roche,Warsaw,Poland)ingroup1,
or bisoprolol 5 mg (Concor; Merck, Warsaw, Poland)
in group 2. The main exclusion criteria were: any
ophthalmic disorders (including glaucoma) and any
systemic diseases requiring vasoactive pharmaco-
therapy or affecting IOP. Additionally, the blood pres-
sure before Doppler examination must have been
lower than 140/90 mmHg. The evaluation of the
CRA ﬂow was carried out twice: before and 3 hours
after taking the examined hypotensive drug. All Dopp-
ler measurements were performed in the vertical posi-
tion. After an application of ultrasound gel, a 10 MHz
probe (DRG Retina Doppler; Tomey, Cambridge,
MA, USA) was positioned over the upper eyelid
temporally to the optical axis of the eye, avoiding
pressure to the eye-ball. Further analysis included:
maximum (systolic) and minimum (diastolic) velocity,
and Pourcellot’s index of resistance (RI). Additionally,
we examined the visual acuity, tonometry, and arterial
blood pressure. The results were analysed with
Wilcoxon’s paired test. All text and table results are
expressed as means ± SE. The study was performed in
the Department of Ophthalmology, Medical Univer-
sity of Silesia in Katowice. The study was approved by
the local ethics committee, and all patients gavewritten
informed consent prior to enrolment.
Results
There were no statistically signiﬁcant differences in
base-line values of blood pressure between the study
groups. Administration of both study drugs resulted
in a substantial systolic and diastolic blood pressure
decrease (Table I). While a signiﬁcant maximum and
minimum blood velocity decrease and a Pourcellot’s
resistance index increase were observed in group
1 patients within 3 hours after bisoprolol 5 mg admin-
istration (Table II), in group 2 patients application of
cilazapril 2.5 mg did not signiﬁcantly affect the exam-
ined blood velocity parameters (Table III).
Discussion
Our preliminary observations showed a different
inﬂuence of BB and ACEI on the blood ﬂow para-
meters within the CRA. Moreover, the obtained
comparable values of blood pressure before and after
both study drugs administration suggest that those
effects are dependent on distinct mechanisms of
action rather than blood pressure reduction degree.
To the best of our knowledge, there are only a
few small and inconsistent studies evaluating the
inﬂuence on ocular circulation parameters of a
short-term therapy or a single administration of an
anti-hypertensive drug in patients with hypertension.
Steigerwalt et al. and others observed an improvement
in central retinal artery ﬂow velocity in hypertensive
patients after a 1-week treatment with trandolapril,
but it did not reach ﬂow parameters observed in
healthy individuals (8). However, Kutschbach et al.
found no changes in perifoveal intercapillary areas
and mean perifoveal capillary velocities assessed in
ﬂuorescein angiograms in patients with hyper-
tension treated with either BB or ACEI or calcium
Table I. Blood pressure before and after administration of hypotensive drugs.
SBP DBP
Base-line After drug administration Base-line After drug administration
Bisoprolol 134.3 ± 2.9 123.2 ± 3.1; P < 0.03 83.6 ± 1.7 75.1 ± 1.6; P < 0.05
Cilazapril 138.1 ± 2.6 125.1 ± 3.3; P < 0.05 84.9 ± 1.1 75.6 ± 1.9; P < 0.05
SBP = systolic blood pressure; DBP = diastolic blood pressure.
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receptor blockers (ARBs), while candesartan mono-
therapy was shown to restore the proper vascular
reactivity (10), valsartan increased blood ﬂow velocity
and decreased the resistance index of the CRA in
essential hypertension (11), and it did not improve
retinal endothelial function in elderly hyperten-
sive patients (12). Moreover, Schocket et al. and
others did not observe any substantial improvement
in retinal blood ﬂow in volunteers after oral admin-
istration of felodipine (13).
The above-described effects might be related to the
different impact of anti-hypertensive drugs on micro-
circulation and endothelium function. Apart from
the third-generation agents, studies on beta-blocker
effects on endothelial function showed inconsistent
results. The majority of studies demonstrated that
ACEIs improve microcirculation endothelial func-
tion. ACEIs, especially agents with afﬁnity to tissue
RAS (cilazapril), not only efﬁciently inhibit angioten-
sin II inﬂuence on endothelium, but also enhance
bradykinin-induced vasodilatation (14). In a double-
blind randomized study, patients with essential hyper-
tension treated with either atenolol or irbesartan
showed comparable, well controlled blood pressure.
However, gluteal subcutaneous biopsies revealed
small arteries structure and function improvement
only in individuals treated with irbesartan (15).
All major components of RAS have been identiﬁed
within the retina of humans and rodents. However,
the inﬂuence of systemically used ACEIs on CRA
ﬂow parameters has hardly been evaluated. The small
and non-signiﬁcant increase of velocity and decrease
of vascular resistance suggest similar effects to
systemic circulation.
Isolated human posterior ciliary arteries and
monkeys’ ophthalmic and ciliary arteries have been
shown to contract mainly in response to noradrena-
line and alpha-1 adrenoreceptor agonists with a lack
of response to beta-agonists. However, using radioli-
gand binding and auto-radiographic techniques
Elena et al. and others localized beta-adrenoreceptors
in the ocular circulation, particularly around the cil-
iary body and also in bovine retinal arteries (6,16,17).
Acting via alpha-1 receptors, norepinephrine causes
vasoconstriction of posterior ciliary and ophthalmic
arteries. Bisoprolol-induced beta-receptor blockade
may enhance alpha-1 receptor activation and ﬁnally
increase the vascular resistance and decrease the ﬂow
velocity. Additionally, heart rate suppression caused
by beta-blockers may intensify these effects (18,19).
The above results are based on a small study of a
single administration of a hypotensive drug; they
constitute preliminary observations and need to be
veriﬁed in a larger population with a longer treatment
period. Anyhow, the inﬂuence of different hypoten-
sive drugs on ocular circulation parameters in hyper-
tensive patients without glaucoma has not been
evaluated sufﬁciently.
Our results suggest that ACEIs do not disturb or
may slightly improve the blood ﬂow in retinal vessels.
Unfortunately, BBs may cause unfavourable changes
in retinal microcirculation. Those additional effects
might be very important in hypertensive patients with
any pre-existing ocular disorders. Moreover, consid-
ering similarities between ocular and brain vessels,
favourable effects on ocular circulation might
also suggest improvements in brain circulation and
contribute to stroke prevention.
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